Age-adjusted association of homologous recombination genes with ovarian cancer using clinical exomes as controls

Abstract Background Genes in the homologous recombination pathway have shown varying results in the literature regarding ovarian cancer (OC) association. Recent case-control studies have used allele counts alone to quantify genetic associations with cancer. Methods A retrospective case-control study...

Full description

Bibliographic Details
Main Authors: Kevin J. Arvai, Maegan E. Roberts, Rebecca I. Torene, Lisa R. Susswein, Megan L. Marshall, Zhancheng Zhang, Natalie J. Carter, Lauren Yackowski, Erica S. Rinella, Rachel T. Klein, Kathleen S. Hruska, Kyle Retterer
Format: Article
Language:English
Published: BMC 2019-07-01
Series:Hereditary Cancer in Clinical Practice
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13053-019-0119-3
id doaj-84cd957c7ef5414fb2a8517d356d7ae4
record_format Article
spelling doaj-84cd957c7ef5414fb2a8517d356d7ae42020-11-25T02:18:23ZengBMCHereditary Cancer in Clinical Practice1897-42872019-07-011711710.1186/s13053-019-0119-3Age-adjusted association of homologous recombination genes with ovarian cancer using clinical exomes as controlsKevin J. Arvai0Maegan E. Roberts1Rebecca I. Torene2Lisa R. Susswein3Megan L. Marshall4Zhancheng Zhang5Natalie J. Carter6Lauren Yackowski7Erica S. Rinella8Rachel T. Klein9Kathleen S. Hruska10Kyle Retterer11GeneDxGeneDxGeneDxGeneDxGeneDxGeneDxGeneDxGeneDxGeneDxMy Gene TeamGeneDxGeneDxAbstract Background Genes in the homologous recombination pathway have shown varying results in the literature regarding ovarian cancer (OC) association. Recent case-control studies have used allele counts alone to quantify genetic associations with cancer. Methods A retrospective case-control study was performed on 6,182 women with OC referred for hereditary cancer multi-gene panel testing (cases) and 4,690 mothers from trios who were referred for whole-exome sequencing (controls). We present age-adjusted odds ratios (ORAdj) to determine association of OC with pathogenic variants (PVs) in homologous recombination genes. Results Significant associations with OC were observed in BRCA1, BRCA2, RAD51C and RAD51D. Other homologous recombination genes, BARD1, NBN, and PALB2, were not significantly associated with OC. ATM and CHEK2 were only significantly associated with OC by crude odds ratio (ORCrude) or by ORAdj, respectively. However, there was no significant difference between ORCrude and ORAdj for these two genes. The significant association of PVs in BRIP1 by ORCrude (2.05, CI = 1.11 to 3.94, P = 0.03) was not observed by ORAdj (0.87, CI = 0.41 to 1.93, P = 0.73). Interestingly, the confidence intervals of the two effect sizes were significantly different (P = 0.04). Conclusion The lack of association of PVs in BRIP1 with OC by ORAdj is inconsistent with some previous literature and current management recommendations, highlighted by the significantly older age of OC onset for BRIP1 PV carriers compared to non-carriers. By reporting ORAdj, this study presents associations that reflect more informed genetic contributions to OC when compared to traditional count-based methods.http://link.springer.com/article/10.1186/s13053-019-0119-3Ovarian CancerBRIP1Exome sequencing
collection DOAJ
language English
format Article
sources DOAJ
author Kevin J. Arvai
Maegan E. Roberts
Rebecca I. Torene
Lisa R. Susswein
Megan L. Marshall
Zhancheng Zhang
Natalie J. Carter
Lauren Yackowski
Erica S. Rinella
Rachel T. Klein
Kathleen S. Hruska
Kyle Retterer
spellingShingle Kevin J. Arvai
Maegan E. Roberts
Rebecca I. Torene
Lisa R. Susswein
Megan L. Marshall
Zhancheng Zhang
Natalie J. Carter
Lauren Yackowski
Erica S. Rinella
Rachel T. Klein
Kathleen S. Hruska
Kyle Retterer
Age-adjusted association of homologous recombination genes with ovarian cancer using clinical exomes as controls
Hereditary Cancer in Clinical Practice
Ovarian Cancer
BRIP1
Exome sequencing
author_facet Kevin J. Arvai
Maegan E. Roberts
Rebecca I. Torene
Lisa R. Susswein
Megan L. Marshall
Zhancheng Zhang
Natalie J. Carter
Lauren Yackowski
Erica S. Rinella
Rachel T. Klein
Kathleen S. Hruska
Kyle Retterer
author_sort Kevin J. Arvai
title Age-adjusted association of homologous recombination genes with ovarian cancer using clinical exomes as controls
title_short Age-adjusted association of homologous recombination genes with ovarian cancer using clinical exomes as controls
title_full Age-adjusted association of homologous recombination genes with ovarian cancer using clinical exomes as controls
title_fullStr Age-adjusted association of homologous recombination genes with ovarian cancer using clinical exomes as controls
title_full_unstemmed Age-adjusted association of homologous recombination genes with ovarian cancer using clinical exomes as controls
title_sort age-adjusted association of homologous recombination genes with ovarian cancer using clinical exomes as controls
publisher BMC
series Hereditary Cancer in Clinical Practice
issn 1897-4287
publishDate 2019-07-01
description Abstract Background Genes in the homologous recombination pathway have shown varying results in the literature regarding ovarian cancer (OC) association. Recent case-control studies have used allele counts alone to quantify genetic associations with cancer. Methods A retrospective case-control study was performed on 6,182 women with OC referred for hereditary cancer multi-gene panel testing (cases) and 4,690 mothers from trios who were referred for whole-exome sequencing (controls). We present age-adjusted odds ratios (ORAdj) to determine association of OC with pathogenic variants (PVs) in homologous recombination genes. Results Significant associations with OC were observed in BRCA1, BRCA2, RAD51C and RAD51D. Other homologous recombination genes, BARD1, NBN, and PALB2, were not significantly associated with OC. ATM and CHEK2 were only significantly associated with OC by crude odds ratio (ORCrude) or by ORAdj, respectively. However, there was no significant difference between ORCrude and ORAdj for these two genes. The significant association of PVs in BRIP1 by ORCrude (2.05, CI = 1.11 to 3.94, P = 0.03) was not observed by ORAdj (0.87, CI = 0.41 to 1.93, P = 0.73). Interestingly, the confidence intervals of the two effect sizes were significantly different (P = 0.04). Conclusion The lack of association of PVs in BRIP1 with OC by ORAdj is inconsistent with some previous literature and current management recommendations, highlighted by the significantly older age of OC onset for BRIP1 PV carriers compared to non-carriers. By reporting ORAdj, this study presents associations that reflect more informed genetic contributions to OC when compared to traditional count-based methods.
topic Ovarian Cancer
BRIP1
Exome sequencing
url http://link.springer.com/article/10.1186/s13053-019-0119-3
work_keys_str_mv AT kevinjarvai ageadjustedassociationofhomologousrecombinationgeneswithovariancancerusingclinicalexomesascontrols
AT maeganeroberts ageadjustedassociationofhomologousrecombinationgeneswithovariancancerusingclinicalexomesascontrols
AT rebeccaitorene ageadjustedassociationofhomologousrecombinationgeneswithovariancancerusingclinicalexomesascontrols
AT lisarsusswein ageadjustedassociationofhomologousrecombinationgeneswithovariancancerusingclinicalexomesascontrols
AT meganlmarshall ageadjustedassociationofhomologousrecombinationgeneswithovariancancerusingclinicalexomesascontrols
AT zhanchengzhang ageadjustedassociationofhomologousrecombinationgeneswithovariancancerusingclinicalexomesascontrols
AT nataliejcarter ageadjustedassociationofhomologousrecombinationgeneswithovariancancerusingclinicalexomesascontrols
AT laurenyackowski ageadjustedassociationofhomologousrecombinationgeneswithovariancancerusingclinicalexomesascontrols
AT ericasrinella ageadjustedassociationofhomologousrecombinationgeneswithovariancancerusingclinicalexomesascontrols
AT racheltklein ageadjustedassociationofhomologousrecombinationgeneswithovariancancerusingclinicalexomesascontrols
AT kathleenshruska ageadjustedassociationofhomologousrecombinationgeneswithovariancancerusingclinicalexomesascontrols
AT kyleretterer ageadjustedassociationofhomologousrecombinationgeneswithovariancancerusingclinicalexomesascontrols
_version_ 1724882574202896384